Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.
Portsmouth CCG Primary Care Rebate Scheme Policy can be found here.
Please note that Portsmouth CCG will only consider signing up to a rebate that has been reviewed by PrescQIPP.
Current schemes that Portsmouth CCG has signed up to as of November 2020:
|Product||Company||Start date||Effective end date|
|Xgeva (Denosumab 70mg/mL)||Amgen||October 2015||Ongoing|
|Lixiana (Edoxaban)||Daiichi Sankyo||March 2016||December 2024|
|Clexane (Enoxaparin)||Sanofi||November 2016||February 2022|
|Aymes||Aymes International||February 2019||February 2021 (auto-renewal)|
|Clenil modulate (Beclometasone inhaler)||Chiesi Ltd||August 2019||August 2021|
|Longtec (Oxycodone MR)||Qdem||September 2019||September 2021|
|Mezolar Matrix (Fentanyl patch)||Sandoz||October 2019||January 2021|
|Inhixa (Enoxaparin)||Tecdow||December 2020||December 2022|
|Slenyto (Melatonin)||Flynn Pharma Ltd||November 2020||November 2023|